A revolutionary, universal stem cell platform
for muscle regeneration
Phase I Trial Participation: The University of Minnesota is seeking Duchenne muscular dystrophy patients to participate in the Phase I study of MyoPAXon, beginning 2025. For more information, please see the study description here or email mdstemcell@umn.edu
The University of Minnesota holds equity in, and has rights to potential royalties from, Myogenica, the
company that has licensed this trial's stem cell therapy from the University of Minnesota. These interests have
been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
If you would like further information please contact Jon Guden, Associate Director, Conflict of Interest Program,
at jguden@umn.edu
Myogenica was formed in 2022 as a spin out of the University of Minnesota to develop MyoPAXon, an induced pluripotent stem cell (iPSC) platform for muscle regeneration. MyoPAXon has been shown to be effective in regenerating muscle and dramatically improving function in a range of muscular dystrophy models, including Duchenne muscular dystrophy, limb girdle muscular dystrophy and Facioscapulohumeral muscular dystrophy (FSHD). Myogenica’s co-founders are a combination of experts in muscle regeneration, stem cell biology and cell and gene therapy development.
Our Story
Stay in the loop!
Sign up with your email address to receive news and updates.